SCHEMBL6173732

SCHEMBL6173732

NC(=O)c1ccc(C=C2CCc3cc(OCCc4c[nH]cn4)ccc3C2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 9/20 0.46
CYP26A1 O43174 2/20 0.45
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP19A1 P11511 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
F2 P00734 2/20 0.42
ACHE P22303 4/20 0.41
BCHE P06276 3/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173725 1.00 MIF (0.46) MIFCYP26A1MAPTALDH1A1CYP19A1
Hydrochloric Acid SCHEMBL6185257 0.99 MIF (0.45) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6175903 0.92 MIF (0.47) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6175896 0.92 MIF (0.47) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6171954 0.87 MIF (0.51) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6171959 0.87 MIF (0.51) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6173867 0.87 MIF (0.46) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6173864 0.87 MIF (0.46) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6174149 0.87 MIF (0.56) MIFCYP26A1MAPTALDH1A1CYP19A1
SCHEMBL6174152 0.87 MIF (0.56) MIFCYP26A1MAPTALDH1A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966446-B1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER LAMBERT CO (US) 2005-10-19 EP claimed
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase BIKKER JACK (US) 2002-01-17 US claimed
US-6265422-B1 ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY 2001-07-24 US claimed
EP-0966446-B1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER LAMBERT CO (US) 2005-10-19 EP disclosed
US-6528535-B2 Anticancer agents; restenosis WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase BIKKER JACK (US) 2002-01-17 US disclosed
US-6265422-B1 ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY 2001-07-24 US disclosed
US-6133303-A VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 2000-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase FNTA, FNTB, SREBF1 MIF 339/4885CYP26A1 2409/4885MAPT 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.